ALSO NOTED: Canada drafting bulk drug rules; Topamax approved for new indication; Schering-Plough wins FDA OK; Neurochem NDA un

> As expected, Canadian health officials say they have begun to draft new regulations that would stop bulk drug shipments going south. But the move is unlikely to threaten the online pharmacies currently in operation. Article

> The FDA has approved Johnson & Johnson's Topamax as an initial monotherapy for epilepsy. Release

> The FDA has approved Schering-Plough's Avelox for certain skin infections. Release

> The FDA has agreed to review Neurochem's NDA for Fibrillex, an investigational product candidate for the treatment of Amyloid A (AA) Amyloidosis. Release

> The FDA has accepted two BLAs from Merck for two of its investigational vaccines: Rotateq and Zostavax. Release

> The first Vioxx trial is set to start in less than two weeks in Texas. Story

> The FDA has sent Endo Pharmaceuticals a warning letter over its Lidoderm direct mail pieces. Release

And Finally... Canada's MDS has agreed to refund up to 2 million claims for work that was either covered or already paid by insurers. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.